Medigen Vaccine Biologics (6547) — Capital Reinvestment Ratio
Latest as of December 2025:
0.03x
Medigen Vaccine Biologics (6547) has a Capital Reinvestment Ratio of 0.03x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$101.08 Million) in capital expenditures (NT$3.54 Million). See Medigen Vaccine Biologics free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.03x
Capex / Operating Cash Flow
Operating Cash Flow
NT$101.08 Million
TWD
Capital Expenditures
NT$3.54 Million
TWD
Data as of
Dec 2025
Most recent filing
Medigen Vaccine Biologics Capital Reinvestment Ratio (2015–2024)
This chart tracks Medigen Vaccine Biologics's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for Medigen Vaccine Biologics (2015–2024)
Year-by-year Capital Reinvestment Ratio for Medigen Vaccine Biologics from 2015 to 2024. For live market cap and broader valuation context, see how much is Medigen Vaccine Biologics worth.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.86x | NT$40.75 Million | NT$34.98 Million | ▲ +268.8% |
| 2021 | 0.23x | NT$579.89 Million | NT$134.97 Million | ▼ -89.0% |
| 2015 | 2.11x | NT$216.26 Million | NT$457.15 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow